The biotech rebound is real. The ladder isn't.

A two-speed market has taken the place of a recovery. Across at least 68 biotech companies, $9.1 billion in venture capital landed between January and June 2026 — the strongest first half since 2022, according to BioPharma Dive's tracker. That number is not a comeback. It is a concentration event.

Roughly 76% of those dollars flowed through rounds of $100 million or more. A single check — $2.1 billion into Alphabet's AI-drug-discovery shop Isomorphic Labs — accounts for nearly a quarter of the half's total. BioPharma Dive's exit data backs the read: 13 IPOs have already raised $4.5 billion, with Parabilis Medicines and Kailera Therapeutics breaking sector records, and 38 acquisitions mark the fastest M&A start in at least seven years.

What is not back is the bottom of the curve. When capital concentrates at the top, seed-stage founders are not squeezed by bad markets — they are squeezed by selection. Only the rare platform play clears the bar for a megaround, and the small companies that usually feed the next wave cannot find a first check. The aggregate stays calm. The on-ramp burns.

Call it the two-speed cycle. The ceiling on biotech is intact; the ladder underneath it is thinned out, and the next decade of drugs is being written in who got priced in.